Anpac Bio-Medical Science Inc. (NASDAQ: ANPC) stock gained by 0.46% at last close while the ANPC stock price surged by 22.40% in the pre-market trading session. With 142 granted patents as of March 31, 2021, AnPac Bio is a biotechnology firm that works on early cancer screening and diagnosis as well as cancer therapy.
The United States Patent and Trademark Office issued ANPC its first illness treatment patent on June 7, 2021. The invention, which includes 25 claims, covers innovative medical devices for illness diagnosis and treatment. This patent includes new device architectures and techniques for treating biological material. AnPac Bio’s recent patent is the company’s twenty-first in the United States.
ANPC also revealed that its newly formed cancer treatment partnership has received over four million dollars in cash flow from a variety of sources, as evidenced by signed legal documents, to help finance the fabrication of cancer therapy medical devices and subsequent lab tests this year. For additional details on the newly announced cancer treatment business, please see ANPC’s news release dated May 25, 2021.
Dr. Chris Yu, Chairman and CEO of AnPac Bio stated,
ANPC is glad to announce that AnPac Bio has received its first disease treatment patent, which will be assigned to their new cancer treatment joint venture. ANPC is also happy to report that their cancer treatment joint venture has received financing to accelerate its research and development. In terms of technology, market, industry, and client, their main cancer detection business and this potential cancer treatment partnership are projected to have substantial synergy. AnPac Bio has always prioritized technical advancement and the development of a strong patent and intellectual property portfolio in the field of cancer screening and diagnosis. ANPC will sustain their strength in cancer detection by continuing to invest actively in improved cancer treatment and prevention technologies, as well as associated intellectual property.
While assisting the establishment of the upcoming cancer treatment partnership, AnPac Bio will continue to concentrate on its core business of cancer screening.